Definition and management of patients with bladder cancer who fail BCG therapy

Expert Review of Anticancer Therapy

Volumn 9, Issue 6, 2009, Pages 815-820

  Martin, Frances M ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bacillus Calmette Gu rin; BCG failures; Bladder cancer; Intravesical therapy

Indexed keywords

ALPHA INTERFERON; APAZIQUONE; BCG VACCINE; DOCETAXEL; GEMCITABINE; MITOMYCIN C; VALRUBICIN; CYTOKINE;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CYSTECTOMY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; HYPERTHERMIC THERAPY; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; PHOTODYNAMIC THERAPY; REVIEW; TRANSURETHRAL RESECTION; BLADDER TUMOR; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; RISK FACTOR; SALVAGE THERAPY; TIME; TREATMENT FAILURE;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; COMBINED MODALITY THERAPY; CYSTECTOMY; CYTOKINES; HUMANS; RISK FACTORS; SALVAGE THERAPY; TIME FACTORS; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 68849086484     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.35     Document Type: Review

References (45)

1. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 22(12), 1435-1448 (1998).
2. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrant Database Syst. Rev. 4, CD001986 (2000).
3. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette - Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 174(1), 86-91 (2005).
4. Herr HW, Dalbagni G. Defining bacillus Calmette - Guérin refractory superficial bladder tumors. J. Urol. 169(5), 1706-1708 (2003).
5. O'Donnell MA, Boehle A. Treatment options for BCG failures. World J. Urol. 24(5), 481-487 (2006).
6. Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer UE. Analysis of early failures after intravesical instillation therapy with bacille Calmette - Guérin for carcinoma in situ of the bladder. Br J. Urol. 75(2), 180-184 (1995).
7. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur. Urol. 37(Suppl. 1), 9-15 (2000).
8. Han RF, Pan JG. Can intravesical bacillus Calmette - Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6), 1216-1223 (2006).
9. Kamat AM. Intravesical BCG for bladder cancer: how much is enough? Cancer 113(4), 674-676 (2008).
10. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al. Has a 3-fold decreased dose of bacillus Calmette - Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol. 174(4 Pt 1), 1242-1247 (2005).
11. de Boer EC, Rooyakkers SJ, Schamhart DH, de Reijke TM, Kurth KH. BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur. Urol. 48(2), 333-338 (2005).
12. Lamm D. Improving patient outcomes: optimal BCG treatment regimen to prevent progression in superficial bladder cancer. Eur. Urol. Suppl. 5(10), 654-659 (2006).
13. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette - Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, and multicemer study. J. Urol. 176(3), 935-939 (2006).
14. Bui TT, Schellhammer PF. Additional bacillus Calmette - Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49(5), 687-690 (1997).
15. Catalina WJ, Hudson MA, Gillen DP, Androgen GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette - Guérin therapy for superficial bladder cancer. J. Urol. 137(2), 220-224 (1987).
16. Lerner SP, Tangent CM, Surcharge H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol. Oncol. 27(2), 155-159 (2009).
17. Harland SJ, Charig CR, Highman W, Parkinson MC, Riddle PR. Outcome in carcinoma in situ of bladder treated with intravesical bacille Calmette - Guérin. Br. J. Urol. 70(3), 271-275 (1992).
18. Locker CR, Sedgwick JE, Gillett DA. Beware the BCG failures: a review of one institution's results. Eur. Urol. 42(6), 542-546 (2002).
19. Lerner SP, Tangent CM, Surcharge H, Wood D, Crawford ED. Patterns of recurrence and outcomes following induction bacillus Calmette - Guérin for high risk Ta, T1 bladder cancer. J. Urol. 177(5), 1727-1731 (2007).
20. Metallic AR, Kamat IS. Controversial issues and optimal management of stage T1G3 bladder cancer. Expet Rev. Anticancer Ther. 6(8), 1283-1294 (2006).
21. Grossman HB, O'Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus Calmette - Guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev. Urol. 10(4), 281-289 (2008).
22. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 166(4), 1296-1299 (2001).
23. Mahmud SM, Fong B, Fahmy N, Tanguay S, Aprikian AG. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J. Urol. 175(1), 78-83 (2006).
24. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette - Guérin in patients with superficial bladder carcinoma. Swedish - Norwegian Bladder Cancer Study Group. J. Urol. 161(4), 1124-1127 (1999).
25. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette - Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol. 163(3), 761-767 (2000).
26. Gallardo E, Sáenz A, Fernández-Morale LA et al. Intravesical gemcitabine in high-risk, non-muscle invasive transitional cell carcinoma (TCC) of the bladder after BCG failure. Proceeding of the Genitourinary Cancers Symposium, 14-16 February 2008, San Francisco, CA, USA (Abstract 299).
27. Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Intravesical gemcitabine in management of BCG refractory superficial TCC of urinary bladder - our experience. Urol. Oncol. 26(6), 616-619 (2008).
28. Dalbagni G, Russo P, Bochner B et al. Phase II trial of intravesical gemcitabine in bacille Calmette - Guérin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 24(18), 2729-2734 (2006).
29. McKiernan JM, Masson P, Murphy AM et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J. Clin. Oncol. 24(19), 3075-3080 (2006).
30. Puri R, Palit V, Loadman PM et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J. Urol. 176(4 Pt 1), 1344-1348 (2006).
31. Jain A, Phillips RM, Scally AJ, Lenaz G, Beer M, Puri R. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 73(5), 1083-1086 (2009).
32. Fukui I, Sekine H, Kihara K et al. Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. J. Urol. 141(3), 531-534 (1989).
33. Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol. Oncol. (2009) DOI: 10.1016/j.urolonc.2008.11.019.
34. Gallagher BL, Joudi FN, Maymi JL, O'Donnell MA. Impact of previous bacille Calmette - Guérin failure pattern on subsequent response to bacille Calmette - Guérin plus interferon intravesical therapy. Urology 71(2), 297-301 (2008).
35. O'Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter Phase II trial of combination bacillus Calmette - Guérin plus interferon α-2b for superficial bladder cancer. J. Urol. 172(3), 888-893 (2004).
36. Sarosdy MF, Manyak MJ, Sagalowsky AI et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette - Guérin. Urology 51(2), 226-231 (1998).
37. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall - DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J. Urol. 181(3), 1040-1045 (2009).
38. Akcetin Z, Todorov J, Tuzel E et al. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer. Anticancer Res. 25(3A), 1623-1628 (2005).
39. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003).
40. Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 54(1), 126-132 (2008).
41. Solsona E, Climent MA, Iborra I et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a Phase 2 nonrandomized comparative trial with radical cystectomy. Eur. Urol. (2008) DOI: 10.1016/ j.eururo.2008.08.027.
42. Weiss C, Wolze C, Engehausen DG et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J. Clin. Oncol. 24(15), 2318-2324 (2006).
43. Jocham D, von Wietersheim J, Pfluger H et al. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer - a multicentre clinical phase III study]. Aktuelle Urologie 40(2), 91-99 (2009).
44. Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7(1), 43-51 (2006).
45. Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party. World J. Urol. DOI: 10.1007/s00345-009-0384-2 (2009).